350 related articles for article (PubMed ID: 21490083)
21. Cardioprotection mediated by rosiglitazone, a peroxisome proliferator-activated receptor gamma ligand, in relation to nitric oxide.
Gonon AT; Bulhak A; Labruto F; Sjöquist PO; Pernow J
Basic Res Cardiol; 2007 Jan; 102(1):80-9. PubMed ID: 16900441
[TBL] [Abstract][Full Text] [Related]
22. Rosiglitazone, an agonist of peroxisome proliferator-activated receptor gamma, reduces pulmonary inflammatory response in a rat model of endotoxemia.
Liu D; Zeng BX; Zhang SH; Yao SL
Inflamm Res; 2005 Nov; 54(11):464-70. PubMed ID: 16307220
[TBL] [Abstract][Full Text] [Related]
23. Regulation of murine macrophage proinflammatory and anti-inflammatory cytokines by ligands for peroxisome proliferator-activated receptor-gamma: counter-regulatory activity by IFN-gamma.
Alleva DG; Johnson EB; Lio FM; Boehme SA; Conlon PJ; Crowe PD
J Leukoc Biol; 2002 Apr; 71(4):677-85. PubMed ID: 11927655
[TBL] [Abstract][Full Text] [Related]
24. Antibodies to nerve growth factor reverse established tactile allodynia in rodent models of neuropathic pain without tolerance.
Wild KD; Bian D; Zhu D; Davis J; Bannon AW; Zhang TJ; Louis JC
J Pharmacol Exp Ther; 2007 Jul; 322(1):282-7. PubMed ID: 17431136
[TBL] [Abstract][Full Text] [Related]
25. Pioglitazone, a peroxisome proliferator-activated receptor-gamma agonist, attenuates myocardial ischemia-reperfusion injury in mice with metabolic disorders.
Honda T; Kaikita K; Tsujita K; Hayasaki T; Matsukawa M; Fuchigami S; Sugiyama S; Sakashita N; Ogawa H; Takeya M
J Mol Cell Cardiol; 2008 May; 44(5):915-26. PubMed ID: 18436235
[TBL] [Abstract][Full Text] [Related]
26. Inhibition of the cyclic adenosine monophosphate pathway attenuates neuropathic pain and reduces phosphorylation of cyclic adenosine monophosphate response element-binding in the spinal cord after partial sciatic nerve ligation in rats.
Liou JT; Liu FC; Hsin ST; Yang CY; Lui PW
Anesth Analg; 2007 Dec; 105(6):1830-7, table of contents. PubMed ID: 18042889
[TBL] [Abstract][Full Text] [Related]
27. Intrathecal rosiglitazone acts at peroxisome proliferator-activated receptor-gamma to rapidly inhibit neuropathic pain in rats.
Churi SB; Abdel-Aleem OS; Tumber KK; Scuderi-Porter H; Taylor BK
J Pain; 2008 Jul; 9(7):639-49. PubMed ID: 18387855
[TBL] [Abstract][Full Text] [Related]
28. Rosiglitazone, an agonist of peroxisome proliferator-activated receptor gamma, reduces chronic colonic inflammation in rats.
Sánchez-Hidalgo M; Martín AR; Villegas I; Alarcón De La Lastra C
Biochem Pharmacol; 2005 Jun; 69(12):1733-44. PubMed ID: 15876425
[TBL] [Abstract][Full Text] [Related]
29. Discovery of tetrahydropyrido[4,3-d]pyrimidine derivatives for the treatment of neuropathic pain.
Sharma M; Deekshith V; Semwal A; Sriram D; Yogeeswari P
Bioorg Chem; 2014 Feb; 52():69-76. PubMed ID: 24368171
[TBL] [Abstract][Full Text] [Related]
30. Keratinocyte-derived vascular endothelial growth factor biosynthesis represents a pleiotropic side effect of peroxisome proliferator-activated receptor-gamma agonist troglitazone but not rosiglitazone and involves activation of p38 mitogen-activated protein kinase: implications for diabetes-impaired skin repair.
Schiefelbein D; Seitz O; Goren I; Dissmann JP; Schmidt H; Bachmann M; Sader R; Geisslinger G; Pfeilschifter J; Frank S
Mol Pharmacol; 2008 Oct; 74(4):952-63. PubMed ID: 18599600
[TBL] [Abstract][Full Text] [Related]
31. Peroxisome proliferator-activated receptor gamma agonist rosiglitazone attenuates oxyhemoglobin-induced Toll-like receptor 4 expression in vascular smooth muscle cells.
Wu Y; Zhao XD; Zhuang Z; Xue YJ; Cheng HL; Yin HX; Shi JX
Brain Res; 2010 Mar; 1322():102-8. PubMed ID: 20132800
[TBL] [Abstract][Full Text] [Related]
32. Activation of peroxisome proliferator-activated receptor gamma inhibits cell growth via apoptosis and arrest of the cell cycle in human colorectal cancer.
Lin MS; Chen WC; Bai X; Wang YD
J Dig Dis; 2007 May; 8(2):82-8. PubMed ID: 17532820
[TBL] [Abstract][Full Text] [Related]
33. Peroxisome proliferator-activated receptor-gamma agonists induce neuroprotection following transient focal ischemia in normotensive, normoglycemic as well as hypertensive and type-2 diabetic rodents.
Tureyen K; Kapadia R; Bowen KK; Satriotomo I; Liang J; Feinstein DL; Vemuganti R
J Neurochem; 2007 Apr; 101(1):41-56. PubMed ID: 17394460
[TBL] [Abstract][Full Text] [Related]
34. Neuroprotection against focal ischemic brain injury by the peroxisome proliferator-activated receptor-gamma agonist rosiglitazone.
Luo Y; Yin W; Signore AP; Zhang F; Hong Z; Wang S; Graham SH; Chen J
J Neurochem; 2006 Apr; 97(2):435-48. PubMed ID: 16539667
[TBL] [Abstract][Full Text] [Related]
35. Ketamine depresses toll-like receptor 3 signaling in spinal microglia in a rat model of neuropathic pain.
Mei XP; Zhou Y; Wang W; Tang J; Wang W; Zhang H; Xu LX; Li YQ
Neurosignals; 2011; 19(1):44-53. PubMed ID: 21389680
[TBL] [Abstract][Full Text] [Related]
36. Resolution of Inflammation by Resolvin D1 Is Essential for Peroxisome Proliferator-activated Receptor-γ-mediated Analgesia during Postincisional Pain Development in Type 2 Diabetes.
Saito T; Hasegawa-Moriyama M; Kurimoto T; Yamada T; Inada E; Kanmura Y
Anesthesiology; 2015 Dec; 123(6):1420-34. PubMed ID: 26492476
[TBL] [Abstract][Full Text] [Related]
37. Rosiglitazone increases PPARgamma in renal tubular epithelial cells and protects against damage by hydrogen peroxide.
Sommer M; Wolf G
Am J Nephrol; 2007; 27(4):425-34. PubMed ID: 17622750
[TBL] [Abstract][Full Text] [Related]
38. Rosiglitazone induces interleukin-1 receptor antagonist in interleukin-1beta-stimulated rat synovial fibroblasts via a peroxisome proliferator-activated receptor beta/delta-dependent mechanism.
Moulin D; Bianchi A; Boyault S; Sebillaud S; Koufany M; Francois M; Netter P; Jouzeau JY; Terlain B
Arthritis Rheum; 2005 Mar; 52(3):759-69. PubMed ID: 15751073
[TBL] [Abstract][Full Text] [Related]
39. Peroxisome proliferator-activated receptor gamma agonist down-regulates IL-17 expression in a murine model of allergic airway inflammation.
Park SJ; Lee KS; Kim SR; Min KH; Choe YH; Moon H; Chae HJ; Yoo WH; Lee YC
J Immunol; 2009 Sep; 183(5):3259-67. PubMed ID: 19641141
[TBL] [Abstract][Full Text] [Related]
40. Epigenetic augmentation of the macrophage inflammatory protein 2/C-X-C chemokine receptor type 2 axis through histone H3 acetylation in injured peripheral nerves elicits neuropathic pain.
Kiguchi N; Kobayashi Y; Maeda T; Fukazawa Y; Tohya K; Kimura M; Kishioka S
J Pharmacol Exp Ther; 2012 Mar; 340(3):577-87. PubMed ID: 22135382
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
